OC-0278: NAR score as surrogate for disease-free survival in the CAO/ARO/AIO-04 phase 3 rectal cancer trial
نویسندگان
چکیده
منابع مشابه
Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials
The conduct of clinical trials in colorectal cancer has historically relied upon endpoints such as disease-free (DFS) or overall survival (OS). While ideal, these endpoints require long-term follow-up, thus contributing to a slow pace of scientific progress in clinical research. Identification of short-term endpoints to serve as surrogates for DFS and OS would enable more rapid determination of...
متن کاملProgression-free survival as a potential surrogate for overall survival in metastatic breast cancer
BACKGROUND Progression-free survival (PFS) and time to progression (TTP) are frequently used to establish the clinical efficacy of anti-cancer drugs. However, the surrogacy of PFS/TTP for overall survival (OS) remains a matter of uncertainty in metastatic breast cancer (mBC). This study assessed the relationship between PFS/TTP and OS in mBC using a trial-based approach. METHODS WE CONDUCTED ...
متن کاملEvaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
Pooled analyses of chemotherapy trials in metastatic colorectal cancer (mCRC) have suggested that progression-free survival (PFS) is a surrogate endpoint for overall survival (OS). However, this has not been evaluated under current standard-of-care regimens of chemotherapy in combination with targeted therapies. We conducted an analysis of published mCRC trials of chemotherapy and targeted ther...
متن کاملProgression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.
The traditional endpoint for assessing efficacy of chemotherapies for advanced/recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and thr...
متن کاملAre We Making Progress in Lung Cancer Using Progression-Free Survival as a Surrogate End Point?
Non–small-cell lung cancer (NSCLC) is the secondmost common cancer diagnosed in the United States and the leading cause of cancer-related mortality, with an estimated 221 200 newcases and 158 040deaths anticipated in2015.1Despite advances in treatment, 5-year survival remains lowat 16.8% across all patients, and only 2% in patients with stage 4 disease, indicating a need for novel therapies tha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiotherapy and Oncology
سال: 2018
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(18)30588-7